My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Bevacizumab Biosimilar, VEGF Monoclonal Antibody

Bevacizumab Biosimilar, VEGF Monoclonal Antibody

Anti-VEGF-A Humanized Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C001P Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody 1 mg 125.00
C001P Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody 5 mg 500.00
C001P Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody 20 mg 1000.00
C001P.LA Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant 0.5 mg 375.00
Description

C001P: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
Isotype: Human IgG1 kappa.
Source: The monoclonal antibody Bevacizumab biosimilar was produced in the bevacizumab biosimilar CHO stable cell line.
Specificity/Sensitivity: The monoclonal antibody Bevacizumab biosimilar specifically binds to the human VEGF-A.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.
Form of Antibody: 0.2 uM filtered solution, pH 6.2, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The monoclonal antibody Bevacizumab is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

Bevacizumab, the humanized anti-VEGF-A monoclonal antibody, produces angiogenesis inhibition and slows the growth of new blood vessels. As the first clinically available angiogenesis inhibitor in the United States, Bevacizumab is used for treatment of certain metastatic cancers, certain lung cancers, renal cancers, ovarian cancers, breast cancers, and glioblastoma multiforme of the brain.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Syd Labs also provides the following VEGF-A antibody biosimilar:
Lucentis Biosimilar, research grade 

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Related Links

See our Privacy Policy